EMA Recommends Granting a Marketing Authorisation for Vimseltinib By Ogkologos - September 5, 2025 215 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults with symptomatic tenosynovial giant cell tumour Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR For Women Returning from Breast Cancer Treatment, Work Often Changes Involuntarily April 28, 2021 Emergency presentations: what are they, and what do they mean for... April 7, 2022 FDA Approves Durvalumab for Muscle Invasive Bladder Cancer May 2, 2025 How to Talk to Your Kids About Ways to Prevent Cancer July 26, 2022 Load more HOT NEWS Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities FDA Approves Nivolumab in Combination with Chemotherapy for Metastatic Gastric Cancer... FDA Approves Obecabtagene Autoleucel for Adults with Relapsed or Refractory B-Cell... Durvalumab Modestly Improves Survival in Advanced Biliary Tract Cancer
